Wild-type (senile) amyloidosis epidemiology and demographics

Wild-type (senile) amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Wild-type (senile) amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Wild-type (senile) amyloidosis epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Wild-type (senile) amyloidosis epidemiology and demographics
CDC on Wild-type (senile) amyloidosis epidemiology and demographics
Wild-type (senile) amyloidosis epidemiology and demographics in the news
Blogs on Wild-type (senile) amyloidosis epidemiology and demographics
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Wild-type (senile) amyloidosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Epidemiology and Demographics

Incidence

• The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.
• The actual incidence of wild-type (senile) amyloidosis in particular is unknown.

Prevalence

• The prevalence of wild-type (senile) amyloidosis has not been determined.

Mortality rate

• The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.

Age

• Patients with wild-type (senile) amyloidosis are almost always elderly (65 years of age or older).

Race

• There is no racial predilection to